San Francisco, California
London, United Kingdom
Bill Lis is CEO of Portola Pharmaceuticals, Inc., a South San Francisco-based company that trades under “PTLA” on the Nasdaq. Bill joined Portola in 2008. Under his leadership, Portola has advanced several novel compounds into clinical development, executed multiple partnerships, raised over $300 million, and, in 2013, completed an IPO. Want to know how to take your startup public? Bill will tell us what he’s learned from leading Portola.
Mr. Lis joined Portola in 2008 and was appointed chief executive officer in May 2010. During this time, Portola has advanced several novel compounds into clinical development, successfully raised over $300 million in private and public financings, including an initial public offering in 2013, and executed multiple partnerships for its programs. Portola’s two wholly-owned thrombosis programs, betrixaban and andexanet alfa, are in late-stage clinical trials, and its wholly-owned hematologic oncology agent, cerdulatinib, is in a Phase 1/2 proof-of-concept study in patients with hematologic cancers. Prior to serving as CEO, Mr. Lis served as chief operating officer and chief business officer. He has over 20 years of experience in biopharmaceutical sales and marketing, corporate development and management. Mr. Lis previously held positions at Scios, Inc. (a Johnson & Johnson Company) from 2004 to 2007 where he last served as vice president, business and commercial operations, and was responsible for cardiovascular business licensing and commercial operations. He led successful in-licensing activities and commercial launch strategies and activities for Xarelto® (rivaroxaban). Prior to joining Scios, he was senior director of marketing and new products for Millennium Pharmaceuticals, Inc. (previously COR Therapeutics, Inc.), where he directed marketing activities for Integrilin® (eptifibatide). At Rhone-Poulenc Rorer, he was involved in the U.S. sales launch and commercialization of several products, including Lovenox® (enoxaparin). Mr. Lis holds a B.S. from the University of Maryland.